Health News Archive - May 14, 2009
BOSTON, May 14 /PRNewswire-FirstCall/ -- Experts from PAREXEL Consulting will present insights into achieving regulatory approval at the BIO International Convention, to be held May 18-21, 2009 at the Georgia World Congress Center in Atlanta, Georgia.
Survey Respondents' Lives Significantly Impacted After Breaking a Bone Special Council of Health and Women's Groups Formed to Encourage Women to Make Bone Health a Priority Before They Break a Bone WASHINGTON, May 14 /PRNewswire/ --- The Know My Bones Council today announced results from a national Harris Interactive survey, which found that one-out-of-five women with postmenopausal osteoporosis (PMO) are retiring later than anticipated and nearly half (48 percent) blame the current economy.
MOUNTAIN VIEW, Calif., May 14 /PRNewswire/ -- Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced the enrollment of the 500th patient in its Merci Registry, a real-world, international, post-market study of its innovative product, the Merci Retrieval System(TM).
Is the proposed legislative action in the best interests of the people or of politicians' and big pharmaceutical companies' bank accounts? COLLEYVILLE, Texas, May 14 /PRNewswire/ -- Our leading health groups are marching a parade against newly marketed e-cigarettes.
LONDON, May 14 /PRNewswire/ -- Pre-hospital emergency care in the form of ambulances is one of the key factors improving the quality of healthcare across Europe.
SAN DIEGO, May 14 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that it has submitted a New Drug Application (NDA) to the U.S.
- This approval will provide greater convenience and broader access to an effective treatment option to the 50 million Americans(1) suffering from frequent heartburn - Once-daily, prescription-strength Prevacid(R) 24HR is the first OTC proton pump inhibitor approved for the treatment of frequent heartburn in the US since 2003 - Prescription-strength Prevacid 24HR treats frequent heartburn for a full 24 hours BASEL, Switzerland, May 14 /PRNewswire/ -- Novartis announced today that Prevacid(R) 24HR (lansoprazole delayed-release capsules 15 mg) has been approved by the U.S.
-- UCB offers Cimzia(R) (certolizumab pegol), a treatment option for adults with moderately to severely active rheumatoid arthritis and moderate to severe Crohn's disease, to U.S.
MISSISSAUGA, ON, May 14 /PRNewswire-FirstCall/ - YM BioSciences Inc.